Efficacy, Safety, and Tolerability of Pridopidine in Huntington Disease (HD): Results from the Phase II, Double-blind, Placebo-controlled, Dose-Ranging Study, Pride-HD (P2.005)
Karl Kieburtz(Beth Israel Deaconess Medical Center), Michael R. Hayden(University of British Columbia), Beth Borowsky(Teva Pharmaceuticals (United States)), Igor D. Grachev(Teva Pharmaceuticals (United States)), Andrew McGarry(Cooper Medical School of Rowan University), G. Bernhard Landwehrmeyer(Universität Ulm), Eli Eyal(Teva Pharmaceuticals (Israel)), Ralf Reilmann(George Huntington Institute), Juha Savola(Teva Pharmaceuticals (Switzerland)), Spyros Papapetropoulos(Massachusetts General Hospital)
Cited by 10
Related Papers
Huntington disease
|Nature Reviews Disease Primers|2015|1.6k
Mutations in HFE2 cause iron overload in chromosome 1q–linked juvenile hemochromatosis
|Nature Genetics|2003|976